ATE283703T1 - Neurodegenerative-erkrankung verwandtes gen - Google Patents

Neurodegenerative-erkrankung verwandtes gen

Info

Publication number
ATE283703T1
ATE283703T1 AT00907858T AT00907858T ATE283703T1 AT E283703 T1 ATE283703 T1 AT E283703T1 AT 00907858 T AT00907858 T AT 00907858T AT 00907858 T AT00907858 T AT 00907858T AT E283703 T1 ATE283703 T1 AT E283703T1
Authority
AT
Austria
Prior art keywords
neurodegenerative disorder
neurodegenerative disease
related gene
disease related
medicament
Prior art date
Application number
AT00907858T
Other languages
English (en)
Inventor
Roger Wayne Davies
Anthony Philip Payne
Roger Graham Sutcliffe
Original Assignee
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow filed Critical Univ Glasgow
Application granted granted Critical
Publication of ATE283703T1 publication Critical patent/ATE283703T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00907858T 1999-03-09 2000-03-09 Neurodegenerative-erkrankung verwandtes gen ATE283703T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9905218.5A GB9905218D0 (en) 1999-03-09 1999-03-09 Neurodegenerative disorder related gene
PCT/GB2000/000860 WO2000053218A1 (en) 1999-03-09 2000-03-09 Neurodegenerative disorder related gene

Publications (1)

Publication Number Publication Date
ATE283703T1 true ATE283703T1 (de) 2004-12-15

Family

ID=10849132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00907858T ATE283703T1 (de) 1999-03-09 2000-03-09 Neurodegenerative-erkrankung verwandtes gen

Country Status (7)

Country Link
EP (1) EP1189631B1 (de)
JP (1) JP2003511346A (de)
AT (1) ATE283703T1 (de)
AU (1) AU2932100A (de)
DE (1) DE60016405T2 (de)
GB (1) GB9905218D0 (de)
WO (1) WO2000053218A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459424B2 (en) 2002-04-22 2008-12-02 The Borad Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C γ for pain management
US7655401B2 (en) * 2002-09-26 2010-02-02 University Of Washington Methods for identifying subjects susceptible to ataxic neurological disease
WO2005095983A1 (en) * 2004-03-04 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with protein kinase c, gamma (prkcg)
CA2899650A1 (en) * 2012-02-29 2013-09-06 Benitec Biopharma Limited Pain treatment
WO2017123806A1 (en) 2016-01-12 2017-07-20 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
WO2018140647A1 (en) 2017-01-25 2018-08-02 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
WO2019195800A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
WO2019212691A1 (en) * 2018-04-30 2019-11-07 Cedars-Sinai Medical Center Diagnostic and drug screening for molecular signatures of early onset sporadic parkinson's disease
EP4100060B1 (de) 2020-02-06 2024-06-12 Perseus Science Group, LLC In vitro verfahren zur diagnose von verletzungen des zentralen nervensystems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
JPH06279311A (ja) * 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US5922571A (en) * 1997-03-06 1999-07-13 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein kinase C homolog

Also Published As

Publication number Publication date
AU2932100A (en) 2000-09-28
GB9905218D0 (en) 1999-04-28
DE60016405T2 (de) 2005-11-24
JP2003511346A (ja) 2003-03-25
DE60016405D1 (de) 2005-01-05
EP1189631A1 (de) 2002-03-27
WO2000053218A1 (en) 2000-09-14
EP1189631B1 (de) 2004-12-01

Similar Documents

Publication Publication Date Title
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
ATE153704T1 (de) Anti-t-zell rezeptordeterminanten zur behandlung von autoimmunkrankheiten
CY1109557T1 (el) ΠΡΟΣΔΙΟΡΙΣΜΟΣ ΑΝΙΧΝΕΥΣΗΣ ΓΟΝΙΔΙΟΥ ΓΙΑ ΒΕΛΤΙΩΣΗ ΤΗΣ ΠΙΘΑΝΟΤΗΤΑΣ ΑΠΟΤΕΛΕΣΜΑΤΙΚΗΣ ΑΠΟΚΡΙΣΗΣ ΣΕ ΚΑΡΚΙΝΙΚΗ ΘΕΡΑΠΕΙΑ ΑΝΤΑΓΩΝΙΣΤΗ ErbB
DE60023936D1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
ATE302267T1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
ATE320811T1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE60016405D1 (de) Neurodegenerative-erkrankung verwandtes gen
DE69735436D1 (de) Methode zum nachweis von zell-apoptose
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
CY1108568T1 (el) Αναστολεας για διαγνωση και θεραπεια ασθενων με αιμορροφιλια α
Fukui et al. Anti‐inflammatory protective effect of ADAMTS‐13 in murine arthritis models
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
MXPA02009781A (es) Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas.
GB9610281D0 (en) Diagnostic method and apparatus
NO955172L (no) Delesjonsvarianter av protein S med manglende C4BP-bindingsaktivitet, men med APC-kofaktoraktivitet, samt materiale og terapeutiske metoder
DE69738433D1 (de) Rezeptor-tyrosine-kinase gene
DE69734890D1 (de) Rdgb-proteine
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
DE69133067D1 (de) Menschliche cyclin-a-zusammensetzungen, verfahren zu ihrer herstellung, nukleotidsequenz, verfahren und wirkstoffe zur bestimmung oder diagnose von zellvermehrung, verfahren und wirkstoffe zur hemmung der zellvermehrung
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE419370T1 (de) Lentivirale vektoren zur behandlung von schmerzen
ATE303813T1 (de) Verwendung von parvoviren zur verbesserung des allgemeinzustandes bei tumorpatienten oder patienten mit chronischen oder konsumierenden erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties